PHC Corporation has signed a Master Collaboration Agreement with CCRM to work together on the development of primary ...

The preclinical development of T-cell therapies will be managed by Moonlight Bio. Credit: murat photographer/Shutterstock. Leveragen has announced a strategic ...

A recent study reveals that age plays a significant role in the outcomes of intermittent fasting. Researchers from Technical ...

PHC has partnered with CCRM to boost cell quality with advanced T-cell expansion solutions. Takeaway Points  PHC has ...

Adicet Bio, Inc. (NASDAQ:ACET), currently trading at $0.99 with a market capitalization of $81.7 million, is a clinical-stage biopharmaceutical company focused on developing novel cell therapies based ...

Get Instant Summarized Text (Gist) A deep learning tool named MUNIS has been developed to predict CD8 + T cell epitopes with high accuracy, potentially accelerating vaccine development. Utilizing ...

In the absence of direct evidence, the contribution of insertional mutagenesis to the development of T-cell lymphoma is currently unclear. (Funded by Johnson & Johnson and Legend Biotech USA ...

TG Therapeutics will use MaxCyte’s technology to advance toward a clinical trial its azer-cel CAR T-cell therapy for ...

The FDA granted Regenerative Medicine Advanced Therapy designation to NXC-201 for the treatment of relapsed/refractory light ...

The FIRCE-1 trial investigating the CAR T-cell therapy firi-cel in relapsed/refractory large B-cell lymphoma has been ...